Literature DB >> 11991837

Signaling from cytokine receptors that affect TH1 responses

Allison M Hanlon1, Sihyug Jang, Padmini Salgame.   

Abstract

Receptors of the various cytokines although structurally diverse, can yet be grouped into four major families of receptor proteins. Most cytokines that function in the immune system bind to either the Class I or Class II receptor families. Two other important receptor families are the immunoglobulin superfamily receptor and the TNF receptor family. Members of these receptor families also have critical roles in the immune system. A common feature of all these receptor families is that they do not exhibit any intrinsic tyrosine kinase activity. Receptor signaling is initiated through recruitment of kinases and through recruitment of cytosolic proteins to the receptor. In this review we will examine receptor signaling pathways initiated from five receptors that are all involved in either initiating T helper-1 (Th1) responses, or in downregulating Th1 responses. The following receptors: Interleukin (IL)-12, Interferon (IFN), IL-4, IL-10, and Tumor necrosis factor (TNF)-alpha will be examined. Signaling initiated from IL-12, IFN-gamma and TNF-alpha are important for inducing Th1 responses, and on the other hand signaling from IL-4 and IL-10 receptors inhibit Th1 responses. We will also discuss human immunodeficiencies resulting from mutations in the genes that encode the Type I cytokine receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11991837     DOI: 10.2741/hanlon

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  10 in total

1.  Monocytes are primed to produce the Th1 type cytokine IL-12 in normal human pregnancy: an intracellular flow cytometric analysis of peripheral blood mononuclear cells.

Authors:  G P Sacks; C W G Redman; I L Sargent
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

2.  Regulation of innate CD8+ T-cell activation mediated by cytokines.

Authors:  Bailey E Freeman; Erika Hammarlund; Hans-Peter Raué; Mark K Slifka
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

3.  Dendritic cells post-maturation are reprogrammed with heightened IFN-gamma and IL-10.

Authors:  Chang-Qing Xia; Ruihua Peng; Mani Annamalai; Michael J Clare-Salzler
Journal:  Biochem Biophys Res Commun       Date:  2006-12-06       Impact factor: 3.575

4.  Multiscale computational modeling reveals a critical role for TNF-α receptor 1 dynamics in tuberculosis granuloma formation.

Authors:  Mohammad Fallahi-Sichani; Mohammed El-Kebir; Simeone Marino; Denise E Kirschner; Jennifer J Linderman
Journal:  J Immunol       Date:  2011-02-14       Impact factor: 5.422

5.  Anti-inflammatory cytokines directly inhibit innate but not adaptive CD8+ T cell functions.

Authors:  Bailey E Freeman; Christine Meyer; Mark K Slifka
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

6.  Gammadelta T cells mitigate the organ injury and mortality of sepsis.

Authors:  Johannes Tschöp; André Martignoni; Holly S Goetzman; Lisa G Choi; Quan Wang; John G Noel; Cora K Ogle; Timothy A Pritts; Jay A Johannigman; Alex B Lentsch; Charles C Caldwell
Journal:  J Leukoc Biol       Date:  2007-12-06       Impact factor: 4.962

7.  Evaluation of association of maternal IL-10 polymorphisms with risk of preeclampsia by A meta-analysis.

Authors:  Wenchao Yang; Zhenmin Zhu; Jin Wang; Wei Ye; Yong Ding
Journal:  J Cell Mol Med       Date:  2014-09-25       Impact factor: 5.310

8.  Chronic Venous Disease during Pregnancy Causes a Systematic Increase in Maternal and Fetal Proinflammatory Markers.

Authors:  Miguel A Ortega; Ana M Gómez-Lahoz; Lara Sánchez-Trujillo; Oscar Fraile-Martinez; Cielo García-Montero; Luis G Guijarro; Coral Bravo; Juan A De Leon-Luis; Jose V Saz; Julia Bujan; Natalio García-Honduvilla; Jorge Monserrat; Melchor Alvarez-Mon
Journal:  Int J Mol Sci       Date:  2022-08-11       Impact factor: 6.208

9.  Cytokines in cancer immunotherapy.

Authors:  Sylvia Lee; Kim Margolin
Journal:  Cancers (Basel)       Date:  2011-10-13       Impact factor: 6.639

10.  CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation.

Authors:  Pradip Bajgain; Supannikar Tawinwung; Lindsey D'Elia; Sujita Sukumaran; Norihiro Watanabe; Valentina Hoyos; Premal Lulla; Malcolm K Brenner; Ann M Leen; Juan F Vera
Journal:  J Immunother Cancer       Date:  2018-05-10       Impact factor: 13.751

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.